Ketamine Tolerated Dose to Prevent Postpartum Depression and Pain After Cesarean Delivery
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify a tolerable dose for postpartum ketamine infusion
using a maximum tolerated dose (MTD) 3+3 design. A loading dose over 1 hour will be the MTD
variable to be tested, as our data suggest that ketamine side effects occur with the loading
dose.
The subanesthetic ketamine dose will be well tolerated and noted side effects will be
acceptable by postpartum women following cesarean delivery.